Benzinga | Jan 20, 2022 09:55AM EST

Barclays Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $100

Barclays analyst Carter Gould maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $110 to $100.